These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

913 related items for PubMed ID: 16302217

  • 1. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 2. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000 Sep; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 3. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V, Thomas KB, Sauter S, Niemeyer CM, Sutor AH.
    Klin Padiatr; 1999 Sep; 211(4):205-10. PubMed ID: 10472551
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
    Castaman G, Rodeghiero F.
    Haematologica; 1993 Sep; 78(6 Suppl 2):57-60. PubMed ID: 8039761
    [Abstract] [Full Text] [Related]

  • 6. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, van Wering ER, Lo Nigro L, van der Does A, Locatelli F, Basso G, Aricò M.
    J Clin Oncol; 2005 Oct 01; 23(28):7161-7. PubMed ID: 16192600
    [Abstract] [Full Text] [Related]

  • 7. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ, Gu LJ, Song DL, Jiang LM, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Wang YP, Chen J.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 01; 26(1):6-9. PubMed ID: 15946500
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 10. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
    Klug Albertsen B, Schmiegelow K, Schrøder H, Carlsen NT, Rosthøj S, Avramis VI, Jakobsen P.
    Cancer Chemother Pharmacol; 2002 Aug 20; 50(2):117-20. PubMed ID: 12172975
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN, Savva NN, Fedasenka UU, Romancova AS, Krasko OV, Eckert C, von Stackelberg A, Aleinikova OV.
    Leuk Res; 2011 Oct 20; 35(10):1312-20. PubMed ID: 21596436
    [Abstract] [Full Text] [Related]

  • 12. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group.
    Br J Haematol; 2009 Aug 20; 146(3):292-9. PubMed ID: 19500099
    [Abstract] [Full Text] [Related]

  • 13. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A, Wypych A, Rokicka-Milewska R, Siedlecki JA, Kulik J.
    Przegl Lek; 2004 Aug 20; 61 Suppl 2():62-6. PubMed ID: 15686049
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
    Risseeuw-Appel IM, Dekker I, Hop WC, Hählen K.
    Med Pediatr Oncol; 1994 Aug 20; 23(4):335-43. PubMed ID: 8058004
    [Abstract] [Full Text] [Related]

  • 16. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
    Lönnerholm G, Thörn I, Sundström C, Frost BM, Abrahamsson J, Behrendtz M, Heldrup J, Jacobsson S, Li A, Olofsson T, Porwit A, Söderhäll S, Larsson R, Forestier E.
    Leuk Res; 2009 Jan 20; 33(1):46-53. PubMed ID: 18639340
    [Abstract] [Full Text] [Related]

  • 17. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 18. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.
    Leukemia; 2008 Dec 01; 22(12):2193-200. PubMed ID: 18754029
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N, Stewart CF, Zhou Y, Campana D, Coustan-Smith E, Rivera GK, Relling MV, Pui CH, Gajjar A.
    Cancer; 2008 May 01; 112(9):1983-91. PubMed ID: 18318429
    [Abstract] [Full Text] [Related]

  • 20. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
    Yeoh AE, Ariffin H, Chai EL, Kwok CS, Chan YH, Ponnudurai K, Campana D, Tan PL, Chan MY, Kham SK, Chong LA, Tan AM, Lin HP, Quah TC.
    J Clin Oncol; 2012 Jul 01; 30(19):2384-92. PubMed ID: 22614971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.